|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0003873,
umls-concept:C0008109,
umls-concept:C0025677,
umls-concept:C0027540,
umls-concept:C0030705,
umls-concept:C0282461,
umls-concept:C0521115,
umls-concept:C0666743,
umls-concept:C1257890,
umls-concept:C1521761,
umls-concept:C1696465,
umls-concept:C2003941,
umls-concept:C2603343
|
|
pubmed:issue |
9194
|
|
pubmed:dateCreated |
2000-1-18
|
|
pubmed:abstractText |
Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:BreedveldFF,
pubmed-author:EmeryPP,
pubmed-author:FeldmannMM,
pubmed-author:FurstDD,
pubmed-author:HarrimanGG,
pubmed-author:KaldenJJ,
pubmed-author:LipskyPP,
pubmed-author:MainiRR,
pubmed-author:SmolenJJ,
pubmed-author:St ClairE WEW,
pubmed-author:WeismanMM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
354
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1932-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10622295-Adult,
pubmed-meshheading:10622295-Aged,
pubmed-meshheading:10622295-Antibodies, Monoclonal,
pubmed-meshheading:10622295-Antirheumatic Agents,
pubmed-meshheading:10622295-Arthritis, Rheumatoid,
pubmed-meshheading:10622295-Chi-Square Distribution,
pubmed-meshheading:10622295-Double-Blind Method,
pubmed-meshheading:10622295-Female,
pubmed-meshheading:10622295-Humans,
pubmed-meshheading:10622295-Infusions, Intravenous,
pubmed-meshheading:10622295-Male,
pubmed-meshheading:10622295-Methotrexate,
pubmed-meshheading:10622295-Middle Aged,
pubmed-meshheading:10622295-Placebos,
pubmed-meshheading:10622295-Remission Induction,
pubmed-meshheading:10622295-Sensitivity and Specificity,
pubmed-meshheading:10622295-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
|
|
pubmed:affiliation |
The Kennedy Institute of Rheumatology and The Imperial College School of Medicine at Charing Cross Hospital, London, UK. r.maini@ic.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
